☰

Robert B. Kargbo, Ph.D. - Publications

Affiliations: 
2008 North Dakota State University, Fargo, ND, United States 
Area:
Allylation, Medicinal Chemistry
Tree Info Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Kargbo RB. SMARCA2/4 PROTAC for Targeted Protein Degradation and Cancer Therapy. Acs Medicinal Chemistry Letters. 11: 1797-1798. PMID 33062156 DOI: 10.1021/Acsmedchemlett.0C00347  0.3
2020 Kargbo RB. RAF Kinases in Cancer: A Moving Target and Degradation Therapy. Acs Medicinal Chemistry Letters. 11: 1369-1370. PMID 32676141 DOI: 10.1021/Acsmedchemlett.0C00299  0.309
2020 Kargbo RB. Chemically Induced Degradation of FAK-ALK for Application in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1367-1368. PMID 32676140 DOI: 10.1021/Acsmedchemlett.0C00290  0.321
2020 Kargbo RB. PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease. Acs Medicinal Chemistry Letters. 11: 1092-1093. PMID 32550986 DOI: 10.1021/Acsmedchemlett.0C00236  0.324
2020 Kargbo RB. PROTAC Compounds Targeting TRK for Use in Cancer Therapeutics. Acs Medicinal Chemistry Letters. 11: 1090-1091. PMID 32550985 DOI: 10.1021/Acsmedchemlett.0C00235  0.304
2020 Kargbo RB. Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 412-413. PMID 32292542 DOI: 10.1021/Acsmedchemlett.0C00107  0.349
2020 Kargbo RB. BRM Targeting Compounds for the Potential Treatment of Cancer. Acs Medicinal Chemistry Letters. 11: 99-100. PMID 32071673 DOI: 10.1021/Acsmedchemlett.0C00007  0.335
2019 Kargbo RB. PROTAC Degradation of Bromodomain for the Treatment of Hyperplasia and Cancer. Acs Medicinal Chemistry Letters. 10: 1372-1373. PMID 31620218 DOI: 10.1021/Acsmedchemlett.9B00424  0.354
2019 Kargbo RB. PROTAC Degradation of IRAK4 for the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1370-1371. PMID 31620217 DOI: 10.1021/Acsmedchemlett.9B00423  0.353
2019 Kargbo RB. PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer. Acs Medicinal Chemistry Letters. 10: 1367-1369. PMID 31620216 DOI: 10.1021/Acsmedchemlett.9B00397  0.345
2019 Kargbo RB. PROTACs and Targeted Protein Degradation for Treating ALK-Mediated Cancers. Acs Medicinal Chemistry Letters. 10: 1102-1103. PMID 31413792 DOI: 10.1021/Acsmedchemlett.9B00296  0.328
2019 Kargbo RB. Inhibition of ACSS2 for Treatment of Cancer and Neuropsychiatric Diseases. Acs Medicinal Chemistry Letters. 10: 1100-1101. PMID 31413791 DOI: 10.1021/Acsmedchemlett.9B00295  0.354
2019 Kargbo RB. Treatment of Cancer and Alzheimer's Disease by PROTAC Degradation of EGFR. Acs Medicinal Chemistry Letters. 10: 1098-1099. PMID 31413790 DOI: 10.1021/Acsmedchemlett.9B00283  0.341
2019 Kargbo RB. Treatment of Cancers by Inhibition of Isoprenylcysteine Carboxyl Methyltransferase. Acs Medicinal Chemistry Letters. 10: 1024-1025. PMID 31312402 DOI: 10.1021/Acsmedchemlett.9B00269  0.353
2019 Kargbo RB. Treatment of Prostate Cancers and Kennedy's Disease by PROTAC-Androgen Receptor Degradation. Acs Medicinal Chemistry Letters. 10: 701-702. PMID 31097985 DOI: 10.1021/Acsmedchemlett.9B00115  0.317
2018 Kargbo RB. Kinase Inhibitors for Treatment of Cancer and Inflammation. Acs Medicinal Chemistry Letters. 9: 1073-1074. PMID 30429947 DOI: 10.1021/Acsmedchemlett.8B00481  0.347
2018 Kargbo RB. ROR(GMMA)T Modulating Activity for the Treatment of Cancers. Acs Medicinal Chemistry Letters. 9: 590-591. PMID 30034583 DOI: 10.1021/Acsmedchemlett.8B00216  0.312
2018 Kargbo RB. Thiazole Derivatives as Inhibitors for the Treatment of Cancer Cells Resistant. Acs Medicinal Chemistry Letters. 9: 169-170. PMID 29541354 DOI: 10.1021/Acsmedchemlett.8B00069  0.329
2018 Kargbo RB. Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy. Acs Medicinal Chemistry Letters. 9: 167-168. PMID 29541353 DOI: 10.1021/Acsmedchemlett.8B00068  0.313
2017 Kargbo RB. Ubiquitin-Specific Inhibitors for the Treatment of Cancers, Autoimmune, and Infectious Diseases. Acs Medicinal Chemistry Letters. 8: 1211-1212. PMID 29259735 DOI: 10.1021/Acsmedchemlett.7B00449  0.363
2017 Kargbo RB. Chemical Compounds as Inhibitors of Kinase Activity for the Treatment of Cancer and COPD. Acs Medicinal Chemistry Letters. 8: 1209-1210. PMID 29259734 DOI: 10.1021/Acsmedchemlett.7B00448  0.333
2017 Kargbo RB. Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers. Acs Medicinal Chemistry Letters. 8: 911-913. PMID 28947935 DOI: 10.1021/Acsmedchemlett.7B00331  0.352
2017 Kargbo RB. New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders. Acs Medicinal Chemistry Letters. 8: 908-910. PMID 28947934 DOI: 10.1021/Acsmedchemlett.7B00330  0.358
2017 Kraft S, Ryan K, Kargbo RB. Recent Advances in Asymmetric Hydrogenation of Tetrasubstituted Olefins. Journal of the American Chemical Society. PMID 28800391 DOI: 10.1021/Jacs.7B07188  0.303
2013 Kargbo RB, Sajjadi-Hashemi Z, Roy S, Jin X, Herr RJ. Synthesis of 3-benzazepines and azepino[4,5-b]heterocyclic ring systems via intramolecular Friedel-Crafts cyclization Tetrahedron Letters. 54: 2018-2021. DOI: 10.1016/J.Tetlet.2013.02.012  0.302
2012 Cui W, Kargbo RB, Sajjadi-Hashemi Z, Ahmed F, Gauuan JF. Efficient one-pot synthesis of 2-substituted benzimidazoles from triacyloxyborane intermediates Synlett. 247-250. DOI: 10.1055/S-0031-1290129  0.309
2009 Samanta D, Kargbo RB, Cook GR. Asymmetric synthesis of aminochromanes via intramolecular indium-mediated allylation of chiral hydrazones. The Journal of Organic Chemistry. 74: 7183-6. PMID 19702255 DOI: 10.1021/Jo901195G  0.669
2007 Kargbo R, Takahashi Y, Bhor S, Cook GR, Lloyd-Jones GC, Shepperson IR. Readily accessible, modular, and tuneable BINOL 3,3'-perfluoroalkylsulfones: highly efficient catalysts for enantioselective in-mediated imine allylation. Journal of the American Chemical Society. 129: 3846-7. PMID 17352482 DOI: 10.1021/Ja070742T  0.626
2007 Kargbo RB, Cook GR. Stereoselective indium-mediated allylation reactions Current Organic Chemistry. 11: 1287-1309. DOI: 10.2174/138527207782023139  0.552
2005 Cook GR, Kargbo R, Maity B. Catalytic enantioselective indium-mediated allylation of hydrazones. Organic Letters. 7: 2767-70. PMID 15957942 DOI: 10.1021/Ol051160O  0.584
2004 Cook GR, Maity BC, Kargbo R. Highly diastereoselective indium-mediated allylation of chiral hydrazones. Organic Letters. 6: 1741-3. PMID 15151403 DOI: 10.1021/Ol0496172  0.597
2004 Kargbo RB. Synthetic applications of tris(pentafluorophenyl)borane Synlett. 1118-1119. DOI: 10.1055/S-2004-822908  0.301
Show low-probability matches.